Evidence map›Paper›PMID 39500719›Full record

ArticleJournal of cachexia, sarcopenia and muscle2024

Prevalence and Prognostic Value of Cachexia Diagnosed by New Definition for Asian People in Older Patients With Heart Failure.

Takumi Noda, Emi Maekawa, Daichi Maeda, Shota Uchida, Masashi Yamashita, Nobuaki Hamazaki, Kohei Nozaki, Hiroshi Saito, Kazuya Saito, Yuki Ogasahara and 18 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Tumour necrosis factor-Frontiers in nutrition · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Takumi NodaDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.ORCID 0000-0001-8546-8777
Emi MaekawaDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Daichi MaedaDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Shota UchidaDepartment of Rehabilitation, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan.
Masashi YamashitaDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.
Nobuaki HamazakiDepartment of Rehabilitation, Kitasato University Hospital, Sagamihara, Japan.
Kohei NozakiDepartment of Rehabilitation, Kitasato University Hospital, Sagamihara, Japan.
Hiroshi SaitoDepartment of Rehabilitation, Kameda Medical Center, Kamogawa, Japan.
Kazuya SaitoDepartment of Rehabilitation, The Sakakibara Heart Institute of Okayama, Okayama, Japan.
Yuki OgasaharaDepartment of Nursing, The Sakakibara Heart Institute of Okayama, Okayama, Japan.
Masaaki KonishiDivision of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
Takeshi KitaiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Kentaro IwataDepartment of Rehabilitation, Kobe City Medical Center General Hospital, Kobe, Japan.
Kentaro JujoDepartment of Cardiology, Nishiarai Heart Center Hospital, Adachi, Japan.
Hiroshi WadaDepartment of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Shimotsuke, Japan.
Takatoshi KasaiDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Hirofumi NagamatsuDepartment of Cardiology, Tokai University School of Medicine, Tokyo, Japan.
Tetsuya OzawaDepartment of Rehabilitation, Odawara Municipal Hospital, Odawara, Japan.
Katsuya IzawaDepartment of Rehabilitation, Matsui Heart Clinic, Saitama, Japan.
Shuhei YamamotoDepartment of Rehabilitation, Shinshu University Hospital, Matsumoto, Japan.
Naoki AizawaDepartment of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus, Nishihara, Japan.
Ryusuke YonezawaDepartment of Rehabilitation, Kitasato University Medical Center, Kitamoto, Japan.
Kazuhiro OkaDepartment of Rehabilitation, Saitama Citizens Medical Center, Saitama, Japan.
Junya AkoDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Shin-Ichi MomomuraDirector, Saitama Citizens Medical Center, Saitama, Japan.
Nobuyuki KagiyamaDepartment of Cardiovascular Biology and Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Yuya MatsueDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kentaro KamiyaDepartment of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan.ORCID 0000-0002-7706-9511

Funding

EN Otsuka Pharmaceutical Co. Ltd.Japan Heart Foundation ResearchJapan Society for the Promotion of Science 19K11424Japan Society for the Promotion of Science 21H03309Novartis Pharma
6 · The paper itself

Abstract

backgroundThe Asian Working Group for Cachexia (AWGC) proposed a new definition of cachexia; however, its impact on cachexia prevalence and overlaps with other conditions, such as sarcopenia and malnutrition, are unclear. We investigated these aspects and the prognostic value of cachexia based on the AWGC on mortality in older patients with heart failure (HF).

methodsThis study was a secondary analysis of a prospective multicentre cohort, namely, the FRAGILE-HF cohort study. Older (≥ 65 years) patients who had been hospitalized due to decompensated HF were enrolled. We assessed the presence/absence of cachexia based on the AWGC and Evans' criteria. Sarcopenia and malnutrition based on the Asian Working Group for Sarcopenia 2014 and the Global Leadership Initiative on Malnutrition criteria were also assessed to compare their prevalence and the overlaps between them. Patients were stratified in relation to the presence/absence of cachexia based on the AWGC criteria, and their mortality rates were compared.

resultsOf the 861 enrolled patients (median [interquartile range] age, 80 years [73-85 years]; male, 58.9%), cachexia, as evaluated based on the AWGC and Evans' criteria, sarcopenia and malnutrition, was present in 74.1%, 36.2%, 20.6% and 55.2% of patients, respectively. AWGC-defined cachexia was most common in the four conditions. All-cause death events occurred in 153 (18.1%) patients in 2 years. AWGC-defined cachexia (adjusted hazard ratio [aHRs], 1.442; 95% confidence interval [95% CI], 0.931-2.233; p = 0.101) was not associated with all-cause mortality in older patients with HF after adjusting for other HF prognosis factors, such as the B-type natriuretic peptide and the Meta-Analysis Global Group in Chronic risk score, whereas cachexia evaluated based on Evans's criteria (aHRs, 1.547; 95% CI, 1.118-2.141; p = 0.009), sarcopenia (aHRs, 1.737; 95% CI, 1.214-2.485; p = 0.003), and malnutrition (aHRs, 1.581; 95% CI, 1.094-2.284; p = 0.015) was associated with all-cause mortality.

conclusionsThree-quarters of older patients with HF had cachexia as evaluated by the AWGC criteria, and this was not associated with a worse prognosis. As the new AWGC cachexia criteria will result in a significantly larger proportion of patients being diagnosed with cachexia, the implementation of the criteria in clinical practice requires further consideration.

trial registrationUMIN-CTR unique identifier: UMIN000023929.

Indexed as

Asian PeopleCachexiaHeart FailureAgedAged, 80 and overFemaleHumansMaleMalnutritionPrevalencePrognosisProspective StudiesSarcopeniaAsia Working Group for Cachexiacachexiaheart failuremalnutritionprognosissarcopenia

Identifiers

PMID39500719
PMCPMC11634483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.